Literature DB >> 22226319

Induction and maintenance of anti-influenza antigen-specific nasal secretory IgA levels and serum IgG levels after influenza infection in adults.

Chisa Fujimoto1, Noriaki Takeda, Atsushi Matsunaga, Ayako Sawada, Takeshi Tanaka, Takashi Kimoto, Wakako Shinahara, Takako Sawabuchi, Miyoko Yamaguchi, Masaki Hayama, Hiroaki Yanagawa, Mihiro Yano, Hiroshi Kido.   

Abstract

OBJECTIVES: To determine the induction and changes in anti-influenza virus secretory IgA (s-IgA) levels in nasal washes and serum IgG levels in patients with influenza.
METHODS: The study recruited 16 patients with influenza aged 35.6 ± 9.6 years in 2007/2008 and 2008/2009 seasons. Nasal washes and serum were obtained throughout the first year. Anti-viral s-IgA levels and neutralization activities in nasal washes, and serum anti-viral IgG levels and hemagglutination inhibition (HI) titers were measured.
RESULTS: Anti-viral(H1N1) s-IgA to total IgA ratio and neutralizing antibody titer were low in nasal washes of all patients, whereas serum levels of anti-viral IgG and HI titers varied widely at day 1.4 ± 1.0 postinfection. Both nasal s-IgA and serum IgG levels later increased significantly, reaching peak levels at day 9.6 ± 3.3 postinfection. The induced nasal s-IgA then returned toward the initial levels within 300 days, although the levels at day 143 ± 70 were 3.03-fold of the initial. Individual serum IgG levels also returned toward the initial levels within 300 days, although the mean levels remained high probably because of re-infection in a subgroup of patients. Although influenza A (H3N2) was a minor epidemic subtype in both flu seasons, a significant rise in nasal anti-viral (H3N2) s-IgA levels and a slightly increase in serum IgG levels were noted.
CONCLUSION: Low levels of nasal anti-viral s-IgA and neutralizing antibody were noted compared with a wide range of serum anti-viral IgG and HI titers at the onset of infection. Elevated s-IgA and IgG returned toward the initial levels within 300 days of infection with minor exceptions.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22226319      PMCID: PMC4941696          DOI: 10.1111/j.1750-2659.2011.00330.x

Source DB:  PubMed          Journal:  Influenza Other Respir Viruses        ISSN: 1750-2640            Impact factor:   4.380


  25 in total

1.  Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus.

Authors:  Etsuhisa Takahashi; Kosuke Kataoka; Kazuyuki Fujii; Junji Chida; Dai Mizuno; Makoto Fukui; Kohtaro Fujihashi; Hiroshi Kido
Journal:  Microbes Infect       Date:  2010-05-07       Impact factor: 2.700

2.  Mucosal antibody response induced with a nasal virosome-based influenza vaccine.

Authors:  P Durrer; U Glück; C Spyr; A B Lang; R Zurbriggen; C Herzog; R Glück
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

3.  Production of Plaques in Monolayer Tissue Cultures by Single Particles of an Animal Virus.

Authors:  R Dulbecco
Journal:  Proc Natl Acad Sci U S A       Date:  1952-08       Impact factor: 11.205

4.  Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs.

Authors:  Maki Nishino; Dai Mizuno; Takashi Kimoto; Wakako Shinahara; Akiho Fukuta; Tsunetomo Takei; Kaori Sumida; Seiichiro Kitamura; Hiroshi Shiota; Hiroshi Kido
Journal:  Vaccine       Date:  2009-07-30       Impact factor: 3.641

5.  Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.

Authors:  M L Clements; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

Review 6.  Immunity to influenza in man.

Authors:  R B Couch; J A Kasel
Journal:  Annu Rev Microbiol       Date:  1983       Impact factor: 15.500

7.  A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection.

Authors:  A Goodeve; C W Potter; A Clark; R Jennings; G C Schild; R Yetts
Journal:  J Hyg (Lond)       Date:  1983-02

8.  Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines.

Authors:  B R Murphy; D L Nelson; P F Wright; E L Tierney; M A Phelan; R M Chanock
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

9.  Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine.

Authors:  S I Tamura; H Asanuma; Y Ito; Y Hirabayashi; Y Suzuki; T Nagamine; C Aizawa; T Kurata; A Oya
Journal:  Eur J Immunol       Date:  1992-02       Impact factor: 5.532

10.  Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.

Authors:  F Y Liew; S M Russell; G Appleyard; C M Brand; J Beale
Journal:  Eur J Immunol       Date:  1984-04       Impact factor: 5.532

View more
  8 in total

1.  Similar severity of influenza primary and re-infections in pre-school children requiring outpatient treatment due to febrile acute respiratory illness: prospective, multicentre surveillance study (2013-2015).

Authors:  Andrea Streng; Christiane Prifert; Benedikt Weissbrich; Andreas Sauerbrei; Andi Krumbholz; Ruprecht Schmidt-Ott; Johannes G Liese
Journal:  BMC Infect Dis       Date:  2022-01-04       Impact factor: 3.090

2.  A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats.

Authors:  Jessica L Grieves; Zhiwei Yin; Adolfo Garcia-Sastre; Ignacio Mena; Mark E Peeples; Heidi P Risman; Hannah Federman; Marvin J Sandoval; Russell K Durbin; Joan E Durbin
Journal:  Vaccine       Date:  2018-05-18       Impact factor: 3.641

3.  Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus.

Authors:  Maximillian S Habibi; Agnieszka Jozwik; Spyridon Makris; Jake Dunning; Allan Paras; John P DeVincenzo; Cornelis A M de Haan; Jens Wrammert; Peter J M Openshaw; Christopher Chiu
Journal:  Am J Respir Crit Care Med       Date:  2015-05-01       Impact factor: 30.528

Review 4.  How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions.

Authors:  Elena Gianchecchi; Alessandro Manenti; Otfried Kistner; Claudia Trombetta; Ilaria Manini; Emanuele Montomoli
Journal:  Influenza Other Respir Viruses       Date:  2019-06-21       Impact factor: 4.380

Review 5.  Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses.

Authors:  Matthew K Siggins; Ryan S Thwaites; Peter J M Openshaw
Journal:  Trends Microbiol       Date:  2021-04-08       Impact factor: 17.079

6.  Association between oral health and upper respiratory tract infection among children.

Authors:  Ying Zhou; Shan Jiang; Kar Yan Li; Edward Chin Man Lo; Xiaoli Gao
Journal:  Int Dent J       Date:  2017-09-14       Impact factor: 2.607

7.  Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis.

Authors:  Wakako Shinahara; Etsuhisa Takahashi; Takako Sawabuchi; Masaru Arai; Nobuo Hirotsu; Yoshio Takasaki; Shizuo Shindo; Kyoko Shibao; Takashi Yokoyama; Kiyoshi Nishikawa; Masahiro Mino; Minako Iwaya; Yuji Yamashita; Satoshi Suzuki; Dai Mizuno; Hiroshi Kido
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

8.  A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults.

Authors:  Irina Kiseleva; Irina Isakova-Sivak; Marina Stukova; Marianna Erofeeva; Svetlana Donina; Natalie Larionova; Elena Krutikova; Ekaterina Bazhenova; Ekaterina Stepanova; Kirill Vasilyev; Victoria Matyushenko; Marina Krylova; Julia Galatonova; Aleksey Ershov; Dmitry Lioznov; Erin Grace Sparrow; Guido Torelli; Larisa Rudenko
Journal:  Vaccines (Basel)       Date:  2020-06-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.